PASylation: a biological alternative to PEGylation for extending the plasma half-life of pharmaceutically active proteins

Antibodies against polyethylene glycol in healthy subjects and in patients treated with PEG-conjugated agents

(2012) Ricardo P Garay et al.   Expert Opinion on Drug Delivery

A Novel Long-Acting Human Growth Hormone Fusion Protein (VRS-317): Enhanced In Vivo Potency and Half-Life

(2012) Jeffrey L. Cleland et al.   JOURNAL OF PHARMACEUTICAL SCIENCES

Poly(ethylene glycol) in Drug Delivery: Pros and Cons as Well as Potential Alternatives

(2010) Katrin Knop et al.   ANGEWANDTE CHEMIE-INTERNATIONAL EDITION

PEGylation of therapeutic proteins

(2010) Simona Jevševar et al.   Biotechnology Journal

Targeting HER2

(2010) Diane E. Milenic et al.   mAbs

A survey of left-handed polyproline II helices

(2010) Benjamin J. Stapley et al.   PROTEIN SCIENCE

Growth Hormone: The Expansion of Available Products and Indications

(2009) Sherry L. Franklin et al.   ENDOCRINOLOGY AND METABOLISM CLINICS OF NORTH AMERICA

Cross-Seeding Fibrillation of Q/N-Rich Proteins Offers New Pathomechanism of Polyglutamine Diseases

(2009) Y. Furukawa et al.   JOURNAL OF NEUROSCIENCE

A recombinant polypeptide extends the in vivo half-life of peptides and proteins in a tunable manner

(2009) Volker Schellenberger et al.   NATURE BIOTECHNOLOGY

Mechanism of Coomassie brilliant blue G-250 binding to proteins: a hydrophobic assay for nanogram quantities of proteins

(2008) Christos D. Georgiou et al.   ANALYTICAL AND BIOANALYTICAL CHEMISTRY

PEGylation of somatropin (recombinant human growth hormone): Impact on its clearance in humans

(2008) R. Webster et al.   XENOBIOTICA